日付 | 受信時刻 | ニュースソース | 見出し | コード | 企業名 |
2024/08/26 | 22 : 15 | GlobeNewswire Inc. | New to The Street Announces its Five Corporate Interviews, Airing Episode 591 on the Fox Business Network, Tonight Monday, August 26, 2024, at 10:30 PM PT | NASDAQ:ACXP | Acurx Pharmaceuticals Inc |
2024/08/26 | 20 : 00 | PR Newswire (US) | ACURX PHARMACEUTICALS ANNOUNCES PARTICIPATION AT THE H.C. Wainwright 26th Annual Global Investment Conference | NASDAQ:ACXP | Acurx Pharmaceuticals Inc |
2024/08/19 | 22 : 20 | GlobeNewswire Inc. | New to The Street Announces Episode 590, Five Corporate Interviews, Airing on the Fox Business Network, Tonight Monday, August 19, 2024, at 10:30 PM PT | NASDAQ:ACXP | Acurx Pharmaceuticals Inc |
2024/08/09 | 22 : 30 | GlobeNewswire Inc. | New to The Street TV Announces Episode 583, Five Riveting Business Guest Interviews, Airs on Bloomberg TV as Sponsored Programming, Saturday, August 10, 2024, at 6:30 PM ET | NASDAQ:ACXP | Acurx Pharmaceuticals Inc |
2024/08/09 | 20 : 13 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:ACXP | Acurx Pharmaceuticals Inc |
2024/08/09 | 20 : 01 | PR Newswire (US) | Acurx Pharmaceuticals, Inc. Reports Second Quarter 2024 Results and Provides Business Update | NASDAQ:ACXP | Acurx Pharmaceuticals Inc |
2024/07/17 | 20 : 00 | PR Newswire (US) | USPTO Grants Acurx Pharmaceuticals New Patent for Ibezapolstat to Treat CDI While Reducing Recurrence of Infection and Improving Health of the Gut Microbiome | NASDAQ:ACXP | Acurx Pharmaceuticals Inc |
2024/07/16 | 20 : 00 | PR Newswire (US) | Acurx Pharmaceuticals, Inc. to Discuss Second Quarter 2024 Financial Results on August 9, 2024 Conference Call and Provide Business Update | NASDAQ:ACXP | Acurx Pharmaceuticals Inc |
2024/07/15 | 20 : 00 | PR Newswire (US) | Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results for CDI at Scientific Conference | NASDAQ:ACXP | Acurx Pharmaceuticals Inc |
2024/06/19 | 05 : 14 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ACXP | Acurx Pharmaceuticals Inc |
2024/06/19 | 05 : 11 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ACXP | Acurx Pharmaceuticals Inc |
2024/06/18 | 05 : 14 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:ACXP | Acurx Pharmaceuticals Inc |
2024/06/06 | 22 : 30 | GlobeNewswire Inc. | New to The Street Announces Episode 576, Four Business Guest Interviews, Airs on Bloomberg TV as Sponsored Programming, Tonight, Thursday, June 6, 2024, at 9:30 PM PT | NASDAQ:ACXP | Acurx Pharmaceuticals Inc |
2024/05/15 | 22 : 00 | PR Newswire (US) | Acurx Announces Successful FDA End-of-Phase 2 Meeting and Phase 3 Readiness for Ibezapolstat in the Treatment of C. difficile Infection | NASDAQ:ACXP | Acurx Pharmaceuticals Inc |
2024/05/15 | 20 : 50 | IH Market News | U.S. Index Futures Flat Ahead of April CPI Data Release, Oil Prices Drop | NASDAQ:ACXP | Acurx Pharmaceuticals Inc |
2024/05/15 | 20 : 13 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:ACXP | Acurx Pharmaceuticals Inc |
2024/05/15 | 20 : 00 | PR Newswire (US) | Acurx Pharmaceuticals, Inc. Reports First Quarter 2024 Results and Provides Business Update | NASDAQ:ACXP | Acurx Pharmaceuticals Inc |
2024/05/15 | 05 : 05 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:ACXP | Acurx Pharmaceuticals Inc |
2024/05/02 | 20 : 00 | PR Newswire (US) | Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results at ESCMID Global 2024 Scientific Conference | NASDAQ:ACXP | Acurx Pharmaceuticals Inc |
2024/04/25 | 23 : 12 | PR Newswire (US) | Acurx Pharmaceuticals Announces Presentation of Ibezapolostat Phase 2 Clinical Trial Results at upcoming ESCMID 2024 Scientific Conference | NASDAQ:ACXP | Acurx Pharmaceuticals Inc |
2024/04/23 | 23 : 57 | PR Newswire (US) | Acurx Pharmaceuticals, Inc. to Discuss First Quarter 2024 Financial Results on May 15, 2024 Conference Call and Provide Business Update | NASDAQ:ACXP | Acurx Pharmaceuticals Inc |
2024/03/19 | 20 : 33 | IH Market News | Unilever Initiates Ice Cream Division Spin-Off and Announces Job Cuts; Berkshire Ramps Up Share Buyback Efforts, and More | NASDAQ:ACXP | Acurx Pharmaceuticals Inc |
2024/03/18 | 20 : 12 | IH Market News | Anticipation Builds on Wall Street for Federal Reserve’s Upcoming Policy Moves; WTI and Brent See Upticks | NASDAQ:ACXP | Acurx Pharmaceuticals Inc |
2024/03/18 | 20 : 01 | PR Newswire (US) | Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update | NASDAQ:ACXP | Acurx Pharmaceuticals Inc |
2024/03/04 | 21 : 01 | PR Newswire (US) | Acurx Pharmaceuticals, Inc. to Discuss Fourth Quarter and Full Year 2023 Financial Results on March 18, 2024 Conference Call and Provide Business Update | NASDAQ:ACXP | Acurx Pharmaceuticals Inc |
2024/02/27 | 21 : 01 | PR Newswire (US) | Acurx Announces FDA Has Granted an End of Phase 2 Meeting for Ibezapolstat for C. difficile Infection and the European Medicines Agency Granted SME Designation for Ibezapolstat EU Development | NASDAQ:ACXP | Acurx Pharmaceuticals Inc |
2024/02/23 | 23 : 30 | GlobeNewswire Inc. | New to The Street Announces Line-up of its Corporate Interviews Airing on its Leadership and Business Televised Series | NASDAQ:ACXP | Acurx Pharmaceuticals Inc |
2024/02/16 | 23 : 30 | GlobeNewswire Inc. | New to The Street Airs Episode 556 Featuring Five Corporate Interviews, Broadcast on the FOX Business Network Monday, February 19, 2024, at 10:30 PM PT | NASDAQ:ACXP | Acurx Pharmaceuticals Inc |
2024/02/02 | 23 : 30 | GlobeNewswire Inc. | New to The Street Announces its 553rd Episode TV Line Up, Featuring Five Corporate Guests, Airing on the FOX Business Network, Monday, February 5, 2024, 10:30 PM PT | NASDAQ:ACXP | Acurx Pharmaceuticals Inc |
2024/02/01 | 23 : 33 | GlobeNewswire Inc. | New to The Street TV Announces Episode #552 with its Five Business Guest Interviews, Airs on Bloomberg TV as Sponsored Programming, Tonight, February 1, 2024, at 9:30 PM PT | NASDAQ:ACXP | Acurx Pharmaceuticals Inc |